Form 4: Heron Therapeutics CFO Converts RSUs to Shares

Heron Therapeutics' EVP and CFO, Ira Duarte, acquired 11,694 shares of common stock through the vesting of restricted stock units.

Summary

• Ira Duarte, Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. (HRTX), reported a transaction on October 31, 2025.
• Duarte acquired 11,694 shares of common stock through the vesting of restricted stock units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• Following this transaction, Duarte beneficially owns 179,786 shares of common stock.
• Duarte also holds 152,027 derivative securities in the form of restricted stock units.
• The restricted stock units vest in 16 equal installments, with the vesting schedule commencing one quarter after the grant date of January 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is mildly positive as it reflects a routine executive compensation event (RSU vesting) that increases insider ownership, which can be viewed favorably by investors as it aligns executive and shareholder interests. However, it is not a significant market-moving event.

Positives

• The transaction increases the direct common stock ownership of a key executive, Ira Duarte, potentially aligning management interests more closely with shareholders.
• The vesting of restricted stock units is a routine component of executive compensation, indicating the fulfillment of performance or tenure conditions.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the details of the reported transaction and the ongoing vesting schedule of restricted stock units.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, common across all industries, particularly for publicly traded companies where executive compensation often includes equity awards like restricted stock units. It does not provide specific industry-related insights.

Stakeholder Impact

• Shareholders: Increased direct ownership by a key executive may be viewed positively, signaling confidence and aligning interests.
• Employees: The vesting of RSUs is a standard part of executive compensation, reflecting the company's compensation structure.

Next Steps

• The remaining 152,027 restricted stock units held by Ira Duarte will continue to vest in equal installments according to the established schedule.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Executive Compensation, Ira Duarte